

Brand Institute is proud to have partnered with  
**350 healthcare companies on 850 nonproprietary names,**  
 highlighted by these recent INN approvals

**Important Update:** The 72nd INN Consultation of the World Health Organization is expected to be held in April, 2021 with an expected submission deadline of December 2020 / January 2021.

Company	INN Name	Company	INN Name
AbbVie	elsubrutinib	Leo	orismilast
AbbVie	mirzotamab	Lin	tinlarebant
AbbVie	mirzotamab clezutoclax	Medeor	firzotemcel
AbbVie	navocafort	Naurex	zelquistinel
Actinium	actinium (225Ac) lintuzumab	Origin	fosdenopterin
	satetraxetan	Outpost	pregabalin arenacarbil
Adaptimmune	letetresgene autoleucel	Pharmazz	centhaquine
Adaptimmune	olitresgene autoleucel	Pharmazz	sovateptide
Amgen	olpasiran	Phosplatin	imifoplatin
Amgen	tapotoclax	Pieris	cinrebafusp alfa
Amgen	zelminemab	Principia	rilzabrutinib
Antibe	otenaproxesul	ProMetic	fezagepras
AstraZeneca	navafenterol	R Bio	atleradstrocel
AstraZeneca	velsecorol	Roche	ralmitaront
BerGenBio AS	tilvestamab	Roche	simlukafusp alfa
Bluebird	betibeglogene autotemcel	Roche	tominersen
Bluebird	elivaldogene autotemcel	Sanofi Genzyme	gatralimab
Boston Pharma	avizakimab	Santhera	lonodelestat
Cadent	rimtuzalcap	Shire	lomardexafetamine
Checkpoint	cosibelimab	Solid Bio	zildistrogene varoparovec
Checkpoint	olafertinib	Stemline	felezonexor
Corvidia	ziltivekimab	Syndax	axatilimab
Crinetics	paltusotine	Syros	mevociclib
CytomX	pacmilimab	Takara	mipetresgene autoleucel
CytomX	praluzatamab	Takara	tebrocaltagene autoleucel
CytomX	praluzatamab ravtansine	Takeda	felcisetrag
Daewoong	enavogliflozin	Takeda	mezagitamab
Daiichi Sankyo	obafistat	Takeda	mobocertinib
EA Pharma	milategrast	Takeda	trazpiroben
Generon	efbemalenograstim alfa	Takeda	encelimab
Gilead	lenacapavir	Tesaro	avalotcagene ontaparovec
GNT Pharma	nelonemdaz	Ultragenyx	ezaladcigene resoparovec
HanAll	batoclimab	Voyager	suvodirsen
Insmed	brensocatic	Wave Life Sciences	zanidatamab
Insmed	treprostnil palmitil	Zymeworks	

**DRUG SAFETY INSTITUTE (DSI) NONPROPRIETARY NAMING EXPERT SPOTLIGHT**



**Sophia Fuerst, M.S., M.B.A.**

President, Nonproprietary Names Division  
 Drug Safety Institute

Ms. Fuerst joined Drug Safety Institute's Nonproprietary (USAN/INN) Names Division as Managing Director in 2005, and was promoted to President in 2007. Ms. Fuerst was formerly Director of the USAN Program at the American Medical Association (AMA) and served in various positions during her 18-year tenure with the Program, including AMA senior staff scientist in the area of Drug Nomenclature.

She was involved in negotiations between the USAN Council, pharmaceutical manufacturers and foreign nomenclature agencies. From 1986 to 2005, Ms. Fuerst was responsible for reviewing submissions, classifying compounds, creating new stems when appropriate and approving and adopting new USAN names.

Ms. Fuerst worked as a consultant, from 1999-2000, to the Secretariat of the INN Programme at the World Health Organization (WHO/INN) in Geneva, Switzerland. Ms. Fuerst holds a B.S. in Biology/Chemistry (pre-med) from St. Joseph's College, an M.S. in Medicinal Chemistry from the University of Chicago and an M.B.A. from Governor's State University in Illinois.




**Sandra Van Laan, B.S.**

Vice President, Regulatory Affairs, Nonproprietary Names Division  
 Drug Safety Institute

Ms. Van Laan joined Drug Safety Institute's Nonproprietary (USAN/INN) Names Division as Vice President, Regulatory Affairs, Nonproprietary Division in 2006. Prior to joining DSI, she worked for 26 years at the American Medical Association (AMA). Ms. Van Laan was the Associate Secretary to the United States Adopted Names (USAN) Council and a Senior Research Associate at the AMA within the Division of Science and Technology where she provided pharmaceutical expertise to AMA staff for several publications including Current Medical Information and Technology (CMIT), Current Procedural Technology (CPT) and the Journal of the American Medical Association (JAMA). In her role with the USAN Program she provided structural and mechanistic compound analysis to accurately categorize newly submitted names into the appropriate stem classification and shared the responsibility for devising new stems within the taxonomy of nomenclature, when appropriate. The AMA USAN Program is responsible for evaluating and approving nonproprietary names.

She supplied guidance to pharmaceutical companies on the preparation of submissions to the USAN Council and negotiated name candidates with the members of the USAN Council and INN Expert Committee to obtain scientifically appropriate nonproprietary names for worldwide use. Ms. Van Laan has worked closely with the Food and Drug Administration (FDA), Center for Biologics, Evaluation and Research (CBER), and the United States Pharmacopeial (USP) Convention for the standardization of nonproprietary nomenclature and has participated in regulatory strategic planning sessions and intellectual property protection discussions pertaining to nonproprietary names. Ms. Van Laan co-chaired the Pronunciation Committee that developed the USAN Pronunciation Guidelines that are in use today.

**BRAND INSTITUTE'S 2019 GLOBAL SHARE OF MARKET NAME APPROVALS**



**Corporate Headquarters**

200 SE 1st Street 12th Floor Miami, FL 33131 Telephone: (305) 374-2500 Fax: (305) 374-2504 www.brandinstitute.com

BASEL +41 78-879-4619	BOSTON (781) 602-6044	CHICAGO (312) 475-9600	DALLAS (512) 369-9100	FRANKFURT +49 6196-400-966	LONDON +44 207-240-2200	LOS ANGELES (310) 830-6111	MIAMI (305) 984-6889	NEW YORK (212) 557-2100
OTTAWA (613) 482-1333	RALEIGH-DURHAM (919) 572-9311	ROCKVILLE (301) 984-1055	SAN FRANCISCO (415) 421-3200	SÃO PAULO +55 11 945-364-083	SEATTLE (206) 204-5111	SEOUL +82 6433-9555	TOKYO +81(03) 6861-7517	TORONTO (416) 622-5777